KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Asset Writedowns and Impairment (2018 - 2019)

Aquestive Therapeutics (AQST) has 2 years of Asset Writedowns and Impairment data on record, last reported at $6000.0 in Q3 2019.

  • For Q3 2019, Asset Writedowns and Impairment fell 85.71% year-over-year to $6000.0; the TTM value through Sep 2019 reached $16000.0, changed N/A, while the annual FY2018 figure was $53000.0, N/A changed from the prior year.
  • Asset Writedowns and Impairment reached $6000.0 in Q3 2019 per AQST's latest filing, down from $24000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $42000.0 in Q3 2018 and bottomed at -$20000.0 in Q4 2018.